SuperworthBiomarin Pharmaceutical profit margin BMRN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 2.1%
- Operating margin, 12 months
- 4.4%
- Net margin on a year earlier
- −19.3 pts
- Peer median
- 15.0%
Over the twelve months to Jun 30, 2026, Biomarin Pharmaceutical kept 2.1% of its revenue as net profit, with an operating margin of 4.4% and a gross margin of 76.1%.
Five years earlier its net margin was 43.7%.
The median for 10 large drugmakers of a similar size is 15.0%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 10.8% | 12.7% | 77.7% |
| FY2024 | 15.0% | 17.0% | 79.7% |
| FY2023 | 6.9% | 7.7% | 78.0% |
| FY2022 | 6.8% | 7.1% | 76.9% |
| FY2021 | −3.5% | −4.5% | 74.5% |
| FY2020 | 46.2% | −2.0% | 71.8% |
| FY2019 | −1.4% | −5.9% | 78.9% |
| FY2018 | −5.2% | −8.3% | 78.9% |
| FY2017 | −8.9% | −1.1% | 81.6% |
| FY2016 | −56.4% | −71.9% | 81.2% |
| FY2015 | −19.3% | −12.4% | 82.9% |
| FY2014 | −17.9% | −12.4% | 83.7% |
| FY2013 | −32.2% | −28.4% | 82.5% |
| FY2012 | −22.8% | −22.0% | 81.7% |
| FY2011 | −12.2% | −7.7% | 81.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 2.1% | −19.3 pts | 4.4% | |
| Q1 FY26 | 8.3% | −9.5 pts | 9.7% | |
| Q4 FY25 | 10.8% | −4.1 pts | 12.7% | |
| Q3 FY25 | 16.8% | +5.1 pts | 19.9% | |
| Q2 FY25 | 21.5% | +11.5 pts | 25.3% | |
| Q1 FY25 | 17.8% | +9.4 pts | 21.0% | |
| Q4 FY24 | 15.0% | +8.0 pts | 17.0% | |
| Q3 FY24 | 11.7% | +5.3 pts | 12.7% | |
| Q2 FY24 | 9.9% | +5.4 pts | 10.3% | |
| Q1 FY24 | 8.3% | +5.0 pts | 8.6% | |
| Q4 FY23 | 6.9% | +0.2 pts | 7.7% | |
| Q3 FY23 | 6.4% | +2.2 pts | 5.8% |
Against its peers
Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.
| Company | Profit margin |
|---|---|
| BMRNBiomarin Pharmaceutical | 2.1% |
| CORTCorcept Therapeutics | 6.6% |
| PTGXProtagonist Therapeutics | 29.4% |
| JAZZJazz Pharmaceuticals | 20.4% |
| TGTXTG Therapeutics | 55.2% |
| ALKSAlkermes plc. | 4.0% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| LGNDLigand Pharmaceuticals | 67.9% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| INDVIndivior Pharmaceuticals | 26.7% |
| ARQTArcutis Biotherapeutics | 6.1% |
| Peer median | 15.0% |
Where Biomarin Pharmaceutical ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Biomarin Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.